Irreversible electroporation for pelvic tumors that have come back
Follows adults treated with irreversible electroporation for recurrent pelvic tumors, checking safety and tumor control.
Plain-language title generated from the registry record
Registry title: Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Key facts
- Where
- Amsterdam, NetherlandsSee the site
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC, location VUmc
- Trial code
- NCT07782164
- Record updated
- 28 August 2026
- Original description
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.Read full original descriptionShow less
Irreversible Electroporation (IRE) of Recurrent Pelvic Tumors: the PELFIRE Study.
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.
Inclusion: Measurable disease described on pre-treatment imaging (CT/MRI/PET-CT) (max 6 weeks prior); IRE of a recurrent pelvic tumor; Unsuitable for other local therapies (surgery/stereotactic body radiation therapy) as described during the multidisciplinary tumor board.
Exclusion: If the treated tumor was biopsied directly prior to MWA and pathology proves the lesion to represent a benign entity; Inadequate or insufficient data registered; Inadequate or insufficient follow-up.